Latest Nikolaus Friedreich Stories
'We Believe' is a viral social media campaign that sheds light on Friedreich's Ataxia, a rare genetic disease for which there is currently no treatment or cure.
The transfer, via a viral vector, of a normal copy of the gene deficient in patients, allowed to fully and very rapidly cure the heart disease in mice.
AAVLife aimed at advancing gene therapy for cardiomyopathy in Friedreich's ataxia to clinic DOWNINGTOWN, Pa., April 6, 2014 /PRNewswire-USNewswire/ -- The Friedreich's
EPI-743 gains key regulatory endorsement. Downingtown, PA, (PRWEB) March 19, 2014 Edison Pharmaceuticals announced today that the U.S.
EPI-743 in two phase 2 development studies for Friedreich's ataxia MOUNTAIN VIEW, Calif., March 17, 2014 /PRNewswire/ -- Edison Pharmaceuticals today announced that the United States
Repligen Corporation announced that BioMarin Pharmaceutical has acquired the assets in the company’s Histone DeACetylase (HDAC) inhibitor program. Downingtown,
EPI-743 phase 2b Friedreich's ataxia trial fully enrolled. Downingtown, PA (PRWEB) February 04, 2014 Edison Pharmaceuticals today announced that
EPI-743 in phase 2 development for Friedreich's ataxia MOUNTAIN VIEW, Calif., Feb.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.